Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai Sees Huge Potential in Its RAS Inhibitor with 15% of All Cancers Targeted: Research Chief
February 9, 2022
-
BUSINESS Insmed Plots Growth in Japan Biz with Arikayce and More Drugs to Follow
February 8, 2022
-
BUSINESS Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
-
REGULATORY Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
-
BUSINESS Pharma Industry Frets Cost and Deadline of MHLW-Ordered Carcinogen Risk Inspections
February 7, 2022
-
REGULATORY Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
-
BUSINESS Novartis Japan Developing Iptacopan as Priority Product, Initially Targeting 3 Indications
February 4, 2022
-
REGULATORY Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
-
REGULATORY 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
-
BUSINESS 650 Astellas Staffers Choose Voluntary Redundancy, Sales Force Down to 1,200
February 3, 2022
-
REGULATORY DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
-
BUSINESS Sumitomo Dainippon Expects to Get Back on Growth Track in FY2025 after Latuda’s LOE: President
February 2, 2022
-
REGULATORY Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
-
REGULATORY Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
-
ORGANIZATION Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
-
REGULATORY MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
-
BUSINESS Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz
January 27, 2022
-
BUSINESS Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy
January 26, 2022
-
REGULATORY PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
-
BUSINESS Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles
January 24, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…